.jpg "Analysts Conflicted on These Healthcare Names: Miragen Therapeutics Inc (NASDAQ: MGEN), Mallinckrodt (NYSE: MNK) and Eiger Biopharmaceuticals (NASDAQ: EIGR)")
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Miragen Therapeutics Inc (NASDAQ: MGEN), Mallinckrodt (NYSE: MNK) and Eiger Biopharmaceuticals (NASDAQ: EIGR).
Miragen Therapeutics Inc (NASDAQ: MGEN)
In a report released today, Madhu Kumar from B.Riley FBR reiterated a Buy rating on Miragen Therapeutics Inc (NASDAQ: MGEN), with a price target of $18.50. The company’s shares opened today at $7.52.
Kumar commented:
“Yesterday, after market close, 5/16, miRagen Therapeutics (MGEN) announced the presentation of Phase Ib data for lead asset cobomarsen at the Oncology (ASCO) meeting on 6/4 (the abstract can be found here). We consider this presentation a potential key catalyst for MGEN shares, as it could expand cobomarsen’s opportunity beyond lead indication mycosis fungoides (MF) to potentially adult T-cell leukemia/lymphoma (ATLL). We thus reiterate our MGEN Buy rating and $18.50 price target.”
According to TipRanks.com, Kumar is a top 100 analyst with an average return of 42.3% and a 66.7% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Clementia Pharmaceuticals Inc.
Currently, the analyst consensus on Miragen Therapeutics Inc is Strong Buy and the average price target is $16.42, representing an 118.4% upside.
In a report released yesterday, Wedbush also reiterated a Buy rating on the stock with a $19 price target.
See today’s analyst top recommended stocks >>
Mallinckrodt (NYSE: MNK)
B.Riley FBR analyst David Buck assigned a Hold rating to Mallinckrodt (NYSE: MNK) today and set a price target of $15. The company’s shares opened today at $15.58, close to its 52-week low of $11.65.
Buck commented:
“We remain Neutral on Mallinckrodt plc (MNK) and we update our estimates following our model and 10-Q review. Mallinckrodt’s guidance for 2018 remained unchanged after 1Q18 results with adjusted EPS guidance at $6.00-$6.50 and 3%-6% Y/Y sales growth from a 2017 restated base of $2.37 billion. We have cut our free cash flow forecast for 2018 to $501M, in line with commentary of ~$500M from a prior $555.5 million forecast.”
According to TipRanks.com, Buck is a 4-star analyst with an average return of 15.7% and a 73.3% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.
Currently, the analyst consensus on Mallinckrodt is Hold and the average price target is $19.27, representing a 23.7% upside.
In a report issued on May 3, Mizuho Securities also maintained a Hold rating on the stock with a $15 price target.
Eiger Biopharmaceuticals (NASDAQ: EIGR)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Eiger Biopharmaceuticals (NASDAQ: EIGR) today and set a price target of $53. The company’s shares opened today at $12.40.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.2% and a 45.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Eiger Biopharmaceuticals is Strong Buy and the average price target is $25.75, representing a 107.7% upside.
In a report issued on May 9, B.Riley FBR also initiated coverage with a Buy rating on the stock with a $24 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
